Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk
  • Home
  • /
  • Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk
  1. Home /
  2. Archives /
  3. Vol. 44 No. 1 (2023) /
  4. Review Articles

Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk

Authors

  • Justyna Białek Kliniczny Szpital Wojewódzki Nr 2 im. Św. Jadwigi Królowej w Rzeszowie https://orcid.org/0000-0002-8447-3395
  • Karolina Nitka Specjalistyczny Publiczny Szpital Kliniczny nr 1 w Lublinie, Polska https://orcid.org/0000-0001-7070-9224
  • Marta Więckowska-Deroń Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Polska https://orcid.org/0000-0002-7811-8370
  • Monika Leszcz Samodzielny Publiczny Zakład Opieki Zdrowotnej w Radzyniu Podlaskim, Polska https://orcid.org/0000-0002-2041-5890
  • Dominika Ćwik-Błotnicka Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie, Polska https://orcid.org/0009-0003-2556-2800
  • Joanna Borczyk Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Polska https://orcid.org/0009-0003-5757-6668
  • Martyna Lewkowicz 4th Department of Internal Medicine, Lower Silesian Oncology, Pulmonology and Hematology Center in Wroclaw, Poland https://orcid.org/0000-0002-2839-2435

DOI:

https://doi.org/10.12775/JEHS.2023.44.01.018

Keywords

teplizumab, type I diabetes

Abstract

Background and Purpose: Type 1 diabetes is a chronic autoimmune disease from the group of metabolic disorders, where the immune system attacks and destroys the insulin producing cells of the pancreas, leading to hyperglycemia and the need for lifelong exogenous insulin supplementation. This results in increased morbidity, life threatening complications, shortened lifespan and quality of life. So there is an urgent need to develop prevention and treatment for people at risk of developing type 1 diabetes.

Current state of knowledge: Recently, there has been significant progress in the field of immunotherapy with therapeutic strategies that focus on stopping the disease in the presymptomatic stage by preserving residual beta-cell function. Randomized, double-blind clinical trials of teplizumab were conducted in relatives of patients with established type 1 diabetes who had not yet been diagnosed with the disease, but were at high risk of developing clinical disease, based on these studies The FDA has approved teplizumab, under trade name Tzield, as a treatment to delay the onset of type 1 diabetes.

Conclusion: The reviewed research papers present strong evidence that teplizumab halts the severe decline in beta cells and possibly improves their function after treatment in a high-risk population. In addition, the effect persists.

References

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. - Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586. PMID: 31180194; PMCID: PMC6776880.

Teplizumab improves and stabilizes beta cell function in antibody positive high-risk individual- Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980. PMID: 33658358; PMCID: PMC8610022.

New Frontiers in the Treatment of Type 1 Diabetes- Warshauer JT, Bluestone JA, Anderson MS. New Frontiers in the Treatment of Type 1 Diabetes. Cell Metab. 2020 Jan 7;31(1):46-61. doi: 10.1016/j.cmet.2019.11.017. Epub 2019 Dec 12. PMID: 31839487; PMCID: PMC6986815.

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes- Sims EK, Cuthbertson D, Herold KC, Sosenko JM. The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes. Diabetes. 2021 Dec;70(12):2922-2931. doi: 10.2337/db21-0519. Epub 2021 Sep 22. PMID: 34551936; PMCID: PMC8660991.

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective- Sims EK, Besser REJ, Dayan C, Geno Rasmussen C, Greenbaum C, Griffin KJ, Hagopian W, Knip M, Long AE, Martin F, Mathieu C, Rewers M, Steck AK, Wentworth JM, Rich SS, Kordonouri O, Ziegler AG, Herold KC; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022 Apr 1;71(4):610-623. doi: 10.2337/dbi20-0054. PMID: 35316839; PMCID: PMC9114719.

Recent Advances in Immune-Based Therapies for Type 1 Diabetes- Smigoc Schweiger D: Recent Advances in Immune-Based Therapies for Type 1 Diabetes. Horm Res Paediatr 2022. doi: 10.1159/000524866

Felton JL. Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better? Immunohorizons. 2021 Jul 14;5(7):535-542. doi: 10.4049/immunohorizons.2000105. PMID: 34261674.

Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410. doi: 10.1080/19420862.2022.2153410. PMID: 36472472; PMCID: PMC9728470.

Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016 Jul;8(8):889-906. doi: 10.2217/imt-2016-0049. Epub 2016 May 10. PMID: 27161438.

Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ. Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technol Ther. 2020 Dec;22(12):948-953. doi: 10.1089/dia.2020.0305. Epub 2020 Oct 20. PMID: 32833543; PMCID: PMC7757538.

Lord S, Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. F1000Res. 2020 Jul 30;9:F1000 Faculty Rev-827. doi: 10.12688/f1000research.21801.1. PMID: 32789003; PMCID: PMC7400689.

Henríquez-Tejo R, Cartes-Velásquez R. Impacto psicosocial de la diabetes mellitus tipo 1 en niños, adolescentes y sus familias. Revisión de la literatura [Psychosocial impact of type 1 diabetes mellitus in children, adolescents and their families. Literature review]. Rev Chil Pediatr. 2018 Jun;89(3):391-398. Spanish. doi: 10.4067/S0370-41062018005000507. PMID: 29999147.

Monaghan M, Bryant BL, Inverso H, Moore HR, Streisand R. Young Children with Type 1 Diabetes: Recent Advances in Behavioral Research. Curr Diab Rep. 2022 Jun;22(6):247-256. doi: 10.1007/s11892-022-01465-0. Epub 2022 Apr 18. PMID: 35435615; PMCID: PMC9013975.

DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018 Jun 16;391(10138):2449-2462. doi: 10.1016/S0140-6736(18)31320-5. PMID: 29916386; PMCID: PMC6661119.

Akil AA, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J Transl Med. 2021 Apr 1;19(1):137. doi: 10.1186/s12967-021-02778-6. PMID: 33794915; PMCID: PMC8017850.

Marks BE, Wolfsdorf JI. Monitoring of Pediatric Type 1 Diabetes. Front Endocrinol (Lausanne). 2020 Mar 17;11:128. doi: 10.3389/fendo.2020.00128. PMID: 32256447; PMCID: PMC7089921.

von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. Current and future therapies for type 1 diabetes. Diabetologia. 2021 May;64(5):1037-1048. doi: 10.1007/s00125-021-05398-3. Epub 2021 Feb 17. PMID: 33595677; PMCID: PMC8012324.

Chellappan DK, Sivam NS, Teoh KX, Leong WP, Fui TZ, Chooi K, Khoo N, Yi FJ, Chellian J, Cheng LL, Dahiya R, Gupta G, Singhvi G, Nammi S, Hansbro PM, Dua K. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother. 2018 Dec;108:1188-1200. doi: 10.1016/j.biopha.2018.09.138. Epub 2018 Oct 2. PMID: 30372820.

Carr ALJ, Evans-Molina C, Oram RA. Precision medicine in type 1 diabetes. Diabetologia. 2022 Nov;65(11):1854-1866. doi: 10.1007/s00125-022-05778-3. Epub 2022 Aug 22. PMID: 35994083; PMCID: PMC9522741.

Ludvigsson J. Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route. Int J Mol Sci. 2020 Feb 26;21(5):1598. doi: 10.3390/ijms21051598. PMID: 32111075; PMCID: PMC7084272.

Yapanis M, James S, Craig ME, O'Neal D, Ekinci EI. Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. J Clin Endocrinol Metab. 2022 May 17;107(6):e2221-e2236. doi: 10.1210/clinem/dgac034. PMID: 35094087; PMCID: PMC9113815.

Downloads

  • PDF

Published

2023-08-18

How to Cite

1.
BIAŁEK, Justyna, NITKA, Karolina, WIĘCKOWSKA-DEROŃ, Marta, LESZCZ, Monika, ĆWIK-BŁOTNICKA, Dominika, BORCZYK, Joanna and LEWKOWICZ, Martyna. Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk. Journal of Education, Health and Sport. Online. 18 August 2023. Vol. 44, no. 1, pp. 288-299. [Accessed 28 June 2025]. DOI 10.12775/JEHS.2023.44.01.018.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 44 No. 1 (2023)

Section

Review Articles

License

Copyright (c) 2023 Justyna Białek, Karolina Nitka, Marta Więckowska-Deroń, Monika Leszcz, Dominika Ćwik-Błotnicka, Joanna Borczyk, Martyna Lewkowicz

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 509
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

teplizumab, type I diabetes
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop